Objectives: We describe pregnant womens’ access to PMTCT and HAART services and associated birth outcomes in South Africa. Methods: Women recuperating in postnatal wards of a referral hospital participated in an evaluation during February-May 2010 during which their maternity records were examined to describe their access to VCT, CD4 Counts, dual ART or HAART during pregnancy. Results: Of the 1609 women who participated in this evaluation, 39% (95%CI36.7-41.5%) tested HIV-positive during their pregnancy. Of the HIV-positive women 2.9% did not have a CD4 count done and an additional 31.3% did not receive their CD4 results. The majority (96.8%) of the HIV-positive women commenced dual ART at their first antenatal visit independent of their CD4 result. During February-May 2010, 48.0% of the women who had a CD4 result were eligible for HAART (CD4<200 cells/mm 3) and 29.1% of these initiated HAART during pregnancy. Under the current South African PMTCT guidelines 71.1% (95%CI66.4-75.4%) of HIV positive pregnant women could be eligible for HAART (CD4<350 cells/mm 3). There were significantly more preterm births among HIV-positive women (p = 0.01) and women who received HAART were no more at risk of preterm deliveries (AOR 0.73;95%CI0.39-1.36;p = 0.2) as compared to women who received dual ART. Nine (2.4%; 95%CI1.1-4.5%) HIV exposed infants were confirmed HIV infected at birth. The in-utero transmission rate was highest among women who required HAART but did not initiate treatment (8.5%) compared to 2.7% and 0.4% among women who received HAART and women who were not eligible for HAART and received PMTCT prophylaxis respectively. Conclusion: In this urban South African community the antenatal HIV prevalence remains high (39%) and timeous access to CD4 results during pregnancy is limited. Under the current South African guidelines, and assuming that access to CD4 results has improved, more than 70% of HIV-positive pregnant women in this community would be requiring HAART. © 2011 Hussain et al.
This is a cross-sectional evaluation of PMTCT and HAART services and birth outcomes in Umlazi, the second largest township in South Africa with an estimated HIV antenatal prevalence of 40%. The evaluation conducted postnatally comprised of a maternity chart audit conducted in the post delivery wards of Prince Mshiyeni Memorial Hospital during a four month period between February and May 2010. Prince Mshiyeni Hospital is a District/Regional Hospital, supports 17 primary health care clinics and has an annual birth rate of 12,000. A written informed consent from all potential participants was obtained prior to any research activity. The informed consent (Zulu and English) were administered by two trained research assistants. Maternity records of consenting study participants were examined to describe their antenatal attendance, access to voluntary counseling and testing and access to CD4 Counts, AZT/NVP and HAART. Birth outcomes such as stillbirth rate, Low birth weight rate, preterm delivery rate and inutero HIV transmission rates were compared between the 3 categories of women viz. HAART ineligible, HAART eligible/untreated and HAART eligible/treated. A dried blood spot was collected from a subsample of HIV exposed infants at birth for HIV diagnosis by DNA PCR. The following data were collected by chart review: Stata version 10 (StataCorp, Texas, U.S.A) was used to analyse the data. A general descriptive analysis was conducted to address all objectives using median, mean, range and 95%CI where applicable. Maternal characteristics presented as categorical data were compared using the Pearson's chi square test. A multivariate analysis was performed in determining independent associations between birth outcomes, HIV status and exposure to HAART. A p value of <0.05 was considered statistically significant. Data were analysed according to stratification of the study population with CD4200 cells/mm3, HAART ineligible, HAART eligible/untreated and HAART eligible/treated. The study was approved by the Ethics Committee of the Nelson R Mandela School of Medicine. All patient details remained confidential and a written informed consent was obtained from eligible participants.
N/A